Asperpyrone A attenuates RANKL-induced osteoclast formation through inhibiting NFATc1, Ca
Animals
Aspergillus niger
/ chemistry
Biological Products
/ chemistry
Calcium
/ metabolism
Calcium Signaling
/ drug effects
Cells, Cultured
Gene Expression
/ drug effects
Intracellular Space
/ drug effects
Mice
Mice, Inbred C57BL
Molecular Structure
NFATC Transcription Factors
/ antagonists & inhibitors
Naphthalenes
/ chemistry
Osteoclasts
/ drug effects
Osteogenesis
/ drug effects
Oxidative Stress
/ drug effects
Pyrones
/ chemistry
RANK Ligand
/ pharmacology
RAW 264.7 Cells
Reactive Oxygen Species
/ metabolism
Tartrate-Resistant Acid Phosphatase
/ genetics
Asperpyrone A
Ca2+ signalling
osteoclast
osteoporosis
reactive oxygen species
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
27
05
2019
revised:
07
08
2019
accepted:
08
09
2019
pubmed:
16
10
2019
medline:
23
9
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
Imbalance of osteoblast and osteoclast in adult leads to a variety of bone-related diseases, including osteoporosis. Thus, suppressing the activity of osteoclastic bone resorption becomes the main therapeutic strategy for osteoporosis. Asperpyrone A is a natural compound isolated from Aspergillus niger with various biological activities of antitumour, antimicrobial and antioxidant. The present study was designed to investigate the effects of Asperpyrone A on osteoclastogenesis and to explore its underlining mechanism. We found that Asperpyrone A inhibited RANKL-induced osteoclastogenesis in a dose-dependent manner when the concentration reached 1 µm, and with no cytotoxicity until the concentration reached to 10 µm. In addition, Asperpyrone A down-regulated the mRNA and protein expression of NFATc1, c-fos and V-ATPase-d2, as well as the mRNA expression of TRAcP and Ctsk. Furthermore, Asperpyrone A strongly attenuated the RNAKL-induced intracellular Ca
Identifiants
pubmed: 31612613
doi: 10.1111/jcmm.14700
pmc: PMC6850946
doi:
Substances chimiques
Biological Products
0
NFATC Transcription Factors
0
Naphthalenes
0
Pyrones
0
RANK Ligand
0
Reactive Oxygen Species
0
asperpyrone A
0
Tartrate-Resistant Acid Phosphatase
EC 3.1.3.2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8269-8279Informations de copyright
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
J Biol Chem. 2015 Oct 23;290(43):26180-93
pubmed: 26359491
Nat Prod Res. 2019 Jul;33(13):1953-1960
pubmed: 29855204
J Bone Miner Res. 2005 Aug;20(8):1462-71
pubmed: 16007343
J Cell Mol Med. 2019 Dec;23(12):8269-8279
pubmed: 31612613
Proc Jpn Acad Ser B Phys Biol Sci. 2007 Jun;83(5):136-43
pubmed: 24019592
J Cell Physiol. 2018 Jan;233(1):476-485
pubmed: 28294321
Immunol Rev. 2009 Sep;231(1):241-56
pubmed: 19754901
Nat Commun. 2017 Nov 15;8(1):1519
pubmed: 29142196
Molecules. 2018 Jul 02;23(7):
pubmed: 30004401
J Cell Biol. 2000 Jan 24;148(2):333-42
pubmed: 10648566
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13361-2
pubmed: 9811806
J Bone Miner Res. 1999 Oct;14(10):1654-63
pubmed: 10491212
Rheumatol Int. 2008 Feb;28(4):317-21
pubmed: 17823800
Nature. 1999 Jan 28;397(6717):315-23
pubmed: 9950424
Dev Cell. 2002 Dec;3(6):889-901
pubmed: 12479813
J Nat Prod. 2015 Jan 23;78(1):61-8
pubmed: 25574844
Int J Mol Sci. 2018 Jul 16;19(7):
pubmed: 30013004
Arch Osteoporos. 2014;9:182
pubmed: 24847682
Nat Rev Immunol. 2007 Apr;7(4):292-304
pubmed: 17380158
J Bone Miner Res. 2015 Apr;30(4):637-46
pubmed: 25359586
Nat Prod Res. 2020 Sep;34(18):2573-2580
pubmed: 30600725
Int J Mol Sci. 2015 Nov 13;16(11):27087-96
pubmed: 26580592
J Cell Physiol. 2016 Sep;231(9):1983-93
pubmed: 26754483
J Bone Miner Res. 2017 Feb;32(2):397-406
pubmed: 27540894
J Bone Miner Res. 2011 Mar;26(3):644-56
pubmed: 20814972
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8643-8
pubmed: 18552177
Sci Rep. 2016 Nov 08;6:36662
pubmed: 27821837
Biochem Biophys Res Commun. 1992 Mar 31;183(3):1153-8
pubmed: 1567393
Cell. 1998 Apr 17;93(2):165-76
pubmed: 9568710
Gene. 2009 Oct 15;446(2):90-8
pubmed: 19563866
J Bone Miner Res. 2000 Nov;15(11):2178-86
pubmed: 11092398
Blood. 2005 Aug 1;106(3):852-9
pubmed: 15817678
JAMA. 2001 Feb 14;285(6):785-95
pubmed: 11176917
Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii83-5
pubmed: 14532157
J Biol Chem. 2004 Oct 29;279(44):45969-79
pubmed: 15304486
Bone. 2015 Jun;75:128-37
pubmed: 25708053
J Clin Invest. 2004 Aug;114(4):475-84
pubmed: 15314684
Molecules. 2016 Jul 20;21(7):
pubmed: 27447606
Front Pharmacol. 2016 Jun 01;7:145
pubmed: 27313530
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nutrients. 2018 Jul 13;10(7):
pubmed: 30011853
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638
pubmed: 19567717
J Biol Chem. 2007 May 25;282(21):15921-9
pubmed: 17403683
Free Radic Biol Med. 2006 May 1;40(9):1483-93
pubmed: 16632109
J Bone Miner Res. 2016 May;31(5):964-74
pubmed: 26684711
Methods Mol Biol. 2010;625:41-53
pubmed: 20422380
J Biol Chem. 2009 May 22;284(21):14667-76
pubmed: 19321441
J Bone Miner Res. 2012 Jun;27(6):1298-1308
pubmed: 22337253
J Cell Biochem. 2018 Jun;119(6):4826-4835
pubmed: 29345352
J Clin Invest. 2008 Nov;118(11):3775-89
pubmed: 18846253